Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II chemotherapy plus immune checkpoint inhibitor followed by conversion surgery for stage IV gastric or gastroesophageal junction adenocarcinoma with a single non-curable factor
jRCTs051220065Phase 2Recruiting
- Sponsor
- Japan Society of Clinical Oncology
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab, nivolumab, trastuzumab, oxaliplatin, tegafur and 3 more in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Japan Society of Clinical Oncology. Primary endpoint: R0 resection rate. Started Oct 2022; status: recruiting.
02
Drugs
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCTs051220065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051220065.